{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-22-000022","form_type":"8-K","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2022-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.259851+00:00","generated_at":"2026-06-27T05:11:32.238107+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Myriad Genetics Q4 revenue up 4% to $160.8M; GAAP EPS $(0.10), adjusted $(0.02)","bullets":["Revenue $160.8M (+4% YoY); full-year $690.6M (+24%). Ex-divested businesses, Q4 revenue up 19%.","GAAP diluted EPS $(0.10); adjusted EPS $(0.02); GAAP gross margin 71.5%, adjusted 71.8%.","Hereditary cancer revenue $74.8M (-5% YoY); pharmacogenomics $29.4M (+63%); prenatal $30.1M (+43%).","FY2022 guidance: revenue $670-700M, adjusted EPS $0.00-$0.20, adjusted gross margin 70-72%.","Ended Q4 with $398.8M cash, no debt; Omicron variant adversely impacted hereditary cancer volumes."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-22-000022","json":"https://secwatch.observer/filing/0000899923-22-000022.json","markdown":"https://secwatch.observer/filing/0000899923-22-000022.md","text":"https://secwatch.observer/filing/0000899923-22-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992322000022/0000899923-22-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992322000022/mygn-20220224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T05:11:32.238107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}